Phillips-Medisize, a Molex company, announced today that it expanded its product portfolio with a new disposable pen injector.
Hudson, Wisconsin-based Phillips-Medisize designed the new injector for high-volume manufacturing. It intends to offer pharmaceutical companies a familiar, competitive pen injector for faster, more efficient and cost-effective market entry.
The company plans to display the pen at Pharmapack Europe, according to a news release.
“A pen injector is an important addition to Phillips-Medisize’s expanding product and platform portfolio that empowers biopharma companies to accelerate the rollout of novel and generic drug treatments at significant economies of scale,” said Paul Chaffin, SVP and president of medical and pharmaceutical solutions, Molex. “This ‘ready to go’ solution offers all of the advantages expected from ‘state of the art’ pen designs while benefiting from our decades of device development and large-volume manufacturing expertise to reduce the challenges of bringing affordable drugs and drug-delivery devices to market.”
More about the design of the new Phillips-Medisize pen injector
Phillips-Medisize designed the pen to match user expectations while offering a “noticeably smaller” option compared to other options on the market.
With a compact form factor, the pen also features a flexible design, the company said. It includes customizable dosing and push-button colors to signal different dosing and drug requirements for multiple therapies. These include diabetes, fertility, growth hormones, obesity and osteoporosis.
The pen injector joins Phillips-Medisize’s Aria smart autoinjector, which it launched in May 2021. It said the duo of offerings can provide biopharma companies more options across the two largest injector market segments.
Phillips-Medisize said it offers sample devices now to support technical evaluation and human factors studies. It plans to make clinical devices available at the end of 2023.
The company said the pen injector could help drug delivery companies respond to the rising market for such devices while reducing commercialization costs and risks.